HomeBiotechNeuroOne Discusses Technology, Upcoming Milestones in Pharma’s Almanac Interview
NeuroOne Discusses Technology, Upcoming Milestones in Pharma’s Almanac Interview
May 31, 2024 - by Catie Corcoran
Medical technology company, NeuroOne (Nasdaq: NMTC) has been featured in Pharma’s Almanac, in an article highlighting the company’s advanced thin-film electrode technology and its potential applications in neurological and neuropsychological treatment.
NeuroOne’s OneRF™ Ablation system is minimally invasive and offers surgeons the ability to perform diagnostics and therapeutic interventions in the same surgical session, reducing the need for multiple procedures, and improving patient recovery times. NeuroOne reported the first implant of its OneRF™ Ablation electrode by doctors at a top ranked hospital in the US in April 2024.
In his interview with Pharma’s Almanac, company President and Chief Executive Officer, Dave Rosa, discussed NeuroOne’s core technology, its benefits for surgeons and patients, and its current and future applications.
“Our technology is a game changer in surgical efficiency. Traditional methods require removing the initial diagnostic electrodes, sending the patient home, then bringing them back for a separate laser surgery, which necessitates drilling new holes in the skull. This not only doubles the invasiveness but also lacks diagnostic feedback, post-ablation,” said Mr. Rosa. “Our electrodes stay in place for both diagnosis and treatment, which means after ablation a surgeon can immediately reconnect the electrodes to diagnostic tools to verify the success of the procedure. And — since the electrodes are still in place — any necessary touch-up work can be performed right there and then. This could potentially eliminate the need for additional surgeries, reduce patient risk, and ensure a more precise outcome.”
Mr. Rosa also discussed upcoming milestones for the company. “Within the next six months, we expect to announce collaborations with pharmaceutical companies for clinical studies using our devices. As a result, our revenue should see a considerable boost as we begin to capitalize on ablation procedures, adding to our existing diagnostic revenue. Additionally, we’re planning to submit for FDA approval new ablation applications in other parts of the body, which could further expand our revenue streams.”
The OneRF™ Ablation system has FDA 510(k) clearance for creation of radiofrequency lesions in nervous tissue for functional neurosurgical procedures.
About NeuroOne
NeuroOne Medical Technologies Corporation is a developmental stage company committed to providing minimally invasive and hi-definition solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson’s disease, dystonia, essential tremors, chronic pain due to failed back surgeries and other related neurological disorders that may improve patient outcomes and reduce procedural costs. The Company may also pursue applications for other areas such as depression, mood disorders, pain, incontinence, high blood pressure, and artificial intelligence. For more information, visit www.nmtc1.com.
Share this article:
Disclaimer
This communication was produced by Prism MarketView, an affiliate of PCG Advisory Inc., (together “PCG”). PCG is an integrated investor relations, communications and strategic advisory firm. The information contained on this is ‘Paid Advertising’ for purposes of Section 17(b) of the Securities Act of 1933, as amended (together with the rules and regulations there under, the “Securities Act”). “PCG” and its affiliates are compensated by respective clients for publicizing information relating to its client’s securities. For more information in terms of compensation received for services provided by PCG, see the pertinent advertising materials relating to the respective client. By accessing this Site and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy…
This communication was produced by Prism MarketView, an affiliate of PCG Advisory Inc., (together “PCG”). PCG is an integrated investor relations, communications and strategic advisory firm. The information contained on this is ‘Paid Advertising’ for purposes of Section 17(b) of the Securities Act of 1933, as amended (together with the rules and regulations there under, the “Securities Act”). “PCG” and its affiliates are compensated by respective clients for publicizing information relating to its client’s securities. For more information in terms of compensation received for services provided by PCG, see the pertinent advertising materials relating to the respective client. By accessing this Site and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy.
“PCG” and its affiliates are not a registered or licensed broker, dealer, broker-dealer, investment adviser nor investment manager, nor does “PCG” engage in any activities that would require such registrations. “PCG” and its affiliates do not provide investment advice, endorsement, analysis or recommendations with respect to any securities, and its services to or statements about its clients should never be construed as any endorsement of or opinion about any security of any client. No information contained in this communication constitutes an offer to sell, a solicitation of an offer to buy, or a recommendation of any security or any other similar product or service regardless of whether such security, product, or service is referenced in this communication.
Our articles, reports/releases and videos are a commercial advertisement and are for general information purposes ONLY. We are engaged in the business of marketing and advertising companies for monetary compensation. We only publish favorable information because we are compensated to publish only favorable information. We are not objective or independent and have multiple conflicts of interest. The Profiled Issuers and parties hiring us have conflicts of interest.
The contributors may buy and sell securities before, during and after any particular article, report and publication. In no event shall “PCG” or affiliates be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or made available by “PCG”, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages.Further, nothing in this communication is intended to provide tax, legal, or investment advice and nothing in this communication should be construed as a recommendation to buy, sell or hold any investment or security or to engage in any investment strategy or transaction. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled. Never invest in any stock featured by “PCG” and its affiliates unless you can afford to lose your entire investment.We urge Investors to conduct their own in-depth investigation of the Profiled Issuers with the assistance of their legal, tax and investment advisers. An investor’s review of the Information should include but not be limited to the Profiled Issuer’s financial condition, operations, management, products or services, trends in the industry and risks that may be material to the profiled Issuer’s business and other information he and his advisers deem material to an investment decision. We encourage our readers to invest carefully and read the investor information available at the web sites of the U.S. Securities and Exchange Commission (SEC) at www.sec.gov and the Financial Industry Regulatory Authority (FINRA) at www.finra.org.
For full disclaimers, including compensation received for professional services, please visit www.pcgadvisory.com/disclosures.
